Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Freda Cooner, Jingjing Ye & Gregory Reaman. (2023) Clinical trial considerations for pediatric cancer drug development. Journal of Biopharmaceutical Statistics 33:6, pages 859-874.
Read now
Read now
Shogo Nomura, Tomohiro Shinozaki & Chikuma Hamada. (2020) Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials. Journal of Biopharmaceutical Statistics 30:2, pages 377-401.
Read now
Read now
Sherko Kümmel, Christian Jackisch, Volkmar Müller, Andreas Schneeweiss, Sandra Klawitter & Michael P Lux. (2018) Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?. Cancer Management and Research 10, pages 5423-5431.
Read now
Read now
Geoffrey Liu, Jie Zhang, Zheng-Yi Zhou, Junlong Li, Xiaopeng Cai & James Signorovitch. (2016) Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer. Current Medical Research and Opinion 32:11, pages 1911-1918.
Read now
Read now
Nicholas R Latimer. (2015) Treatment switching in oncology trials and the acceptability of adjustment methods. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 561-564.
Read now
Read now
Articles from other publishers (22)
Steven D Nathan, Shilpa Johri, Joanna M Joly, Christopher S King, Amresh Raina, Colleen A McEvoy, Dasom Lee, Eric Shen, Peter Smith, Chunqin Deng & Aaron B Waxman. (2023) Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality. Thorax, pages thorax-2023-220821.
Crossref
Crossref
Md. Belal Hossain & Mohammad Ehsanul Karim. (2022) Key considerations for choosing a statistical method to deal with incomplete treatment adherence in pragmatic trials. Pharmaceutical Statistics 22:1, pages 205-231.
Crossref
Crossref
Lilla Di Scala, Marisa Bacchi, Bjørn Bayer & Stefano Turricchia. (2022) Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study. Advances in Therapy 39:9, pages 4346-4358.
Crossref
Crossref
Laura Pazzagli, Marie Linder, Johan Reutfors & Lena Brandt. (2021) The use of uncertain exposure—A method to define switching and add‐on in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety 31:1, pages 28-36.
Crossref
Crossref
José L. Jiménez, Julia Niewczas, Alexander Bore & Carl-Fredrik Burman. (2021) A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching. PLOS ONE 16:11, pages e0259178.
Crossref
Crossref
Mario Ouwens, Annie Darilay, Yiduo Zhang, Pralay Mukhopadhyay, Helen Mann, James Ryan & Phillip A. Dennis. (2021) Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research 95, pages 100640.
Crossref
Crossref
Benjamin Gregory Carlisle, Adélaïde Doussau & Jonathan Kimmelman. (2019) Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials 17:1, pages 18-29.
Crossref
Crossref
Junlong Li, Medha Sasane, Jie Zhang, Jing Zhao, Marie Louise Ricculli, Zhiwen Yao, Suman Redhu & James Signorovitch. (2018) Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data. BMJ Open 8:8, pages e021642.
Crossref
Crossref
Laura Pazzagli, Marie Linder, Mingliang Zhang, Emese Vago, Paul Stang, David Myers, Morten Andersen & Shahram Bahmanyar. (2018) Methods for time-varying exposure related problems in pharmacoepidemiology: An overview. Pharmacoepidemiology and Drug Safety 27:2, pages 148-160.
Crossref
Crossref
Steve J Edwards, Victoria Wakefield, Peter Cain, Charlotta Karner, Kayleigh Kew, Mariana Bacelar, Natalie Masento & Fatima Salih. (2018) Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment 22:6, pages 1-278.
Crossref
Crossref
Billy Amzal, Shuai Fu, Jie Meng, Johanna Lister & Helene Karcher. (2017) Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLOS ONE 12:9, pages e0184423.
Crossref
Crossref
Francisco Cervantes & Arturo Pereira. (2017) Does ruxolitinib prolong the survival of patients with myelofibrosis?. Blood 129:7, pages 832-837.
Crossref
Crossref
Lingling Li, Shijie Tang & Liewen Jiang. (2017) On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropout. Statistics in Medicine.
Crossref
Crossref
James C. YaoMarianne PavelCatherine Lombard-BohasEric Van CutsemMaurizio VoiUlrike BrandtWei HeDavid ChenJaume CapdevilaElisabeth G.E. de VriesPaola TomassettiTimothy HobdayRodney PommierKjell Öberg. (2016) Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Journal of Clinical Oncology 34:32, pages 3906-3913.
Crossref
Crossref
Jin ZhangCong Chen. (2016) Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method. Statistics in Medicine 35:21, pages 3690-3703.
Crossref
Crossref
C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna & T Barbui. (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:8, pages 1701-1707.
Crossref
Crossref
Vinay Prasad & Vance W. Berger. (2015) Hard-Wired Bias. Mayo Clinic Proceedings 90:9, pages 1171-1175.
Crossref
Crossref
Marie-Charlotte Loron, Steven Grange, Dominique Guerrot, Frédéric Di Fiore, Caroline Freguin, Mélanie Hanoy, Frank Le Roy, Gwenaelle Poussard, Isabelle Etienne, Bruno Legallicier, Christian Pfister, Michel Godin & Dominique Bertrand. (2015)
Pneumocystis jirovecii
Pneumonia in Everolimus-Treated Renal Cell Carcinoma
. Journal of Clinical Oncology 33:8, pages e45-e47.
Crossref
Crossref
Margarita García, Valentín Navarro & Ana Clopés. (2014) Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials. Current Colorectal Cancer Reports 10:3, pages 254-262.
Crossref
Crossref
Vinay Prasad & Christine Grady. (2014) The misguided ethics of crossover trials. Contemporary Clinical Trials 37:2, pages 167-169.
Crossref
Crossref
Jan R R LewisWendy L LipworthIan H KerridgeRichard O Day. (2013) The economic evaluation of personalised oncology medicines: ethical challenges. Medical Journal of Australia 199:7, pages 471-473.
Crossref
Crossref
David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Saletan & William Berg. (2013) Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Annals of the New York Academy of Sciences 1291:1, pages 14-32.
Crossref
Crossref